Detail Information of Epigenetic Regulations
General Information of Drug Transporter (DT) | |||||
---|---|---|---|---|---|
DT ID | DTD0252 Transporter Info | ||||
Gene Name | SLC2A10 | ||||
Transporter Name | Glucose transporter type 10 | ||||
Gene ID | |||||
UniProt ID | |||||
Epigenetic Regulations of This DT (EGR) | |||||
---|---|---|---|---|---|
Methylation |
|||||
Bladder cancer |
4 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in bladder cancer | [ 1 ] | |||
Location |
TSS1500 (cg27610561) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-2.34E+00 | Statistic Test | p-value:5.41E-11; Z-score:-9.52E+00 | ||
Methylation in Case |
2.56E-01 (Median) | Methylation in Control | 5.99E-01 (Median) | ||
Studied Phenotype |
Bladder cancer[ ICD-11:2C94] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon2 |
Methylation of SLC2A10 in bladder cancer | [ 1 ] | |||
Location |
TSS200 (cg08038974) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.43E+00 | Statistic Test | p-value:4.38E-02; Z-score:-1.58E+00 | ||
Methylation in Case |
9.26E-02 (Median) | Methylation in Control | 1.33E-01 (Median) | ||
Studied Phenotype |
Bladder cancer[ ICD-11:2C94] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon3 |
Methylation of SLC2A10 in bladder cancer | [ 1 ] | |||
Location |
TSS200 (cg03940556) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.24E+00 | Statistic Test | p-value:4.78E-02; Z-score:-1.64E+00 | ||
Methylation in Case |
8.29E-02 (Median) | Methylation in Control | 1.03E-01 (Median) | ||
Studied Phenotype |
Bladder cancer[ ICD-11:2C94] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon4 |
Methylation of SLC2A10 in bladder cancer | [ 1 ] | |||
Location |
Body (cg10156714) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.35E+00 | Statistic Test | p-value:4.10E-09; Z-score:-1.46E+01 | ||
Methylation in Case |
6.40E-01 (Median) | Methylation in Control | 8.67E-01 (Median) | ||
Studied Phenotype |
Bladder cancer[ ICD-11:2C94] | ||||
Experimental Material |
Patient tissue samples | ||||
Breast cancer |
5 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in breast cancer | [ 2 ] | |||
Location |
TSS1500 (cg27610561) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.25E+00 | Statistic Test | p-value:2.57E-09; Z-score:-2.94E+00 | ||
Methylation in Case |
6.13E-01 (Median) | Methylation in Control | 7.64E-01 (Median) | ||
Studied Phenotype |
Breast cancer[ ICD-11:2C60-2C6Z] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon2 |
Methylation of SLC2A10 in breast cancer | [ 2 ] | |||
Location |
TSS1500 (cg23514532) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.27E+00 | Statistic Test | p-value:3.20E-06; Z-score:1.07E+00 | ||
Methylation in Case |
1.61E-01 (Median) | Methylation in Control | 1.27E-01 (Median) | ||
Studied Phenotype |
Breast cancer[ ICD-11:2C60-2C6Z] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon3 |
Methylation of SLC2A10 in breast cancer | [ 2 ] | |||
Location |
TSS200 (cg03940556) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.16E+00 | Statistic Test | p-value:1.38E-03; Z-score:6.24E-01 | ||
Methylation in Case |
9.34E-02 (Median) | Methylation in Control | 8.08E-02 (Median) | ||
Studied Phenotype |
Breast cancer[ ICD-11:2C60-2C6Z] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon4 |
Methylation of SLC2A10 in breast cancer | [ 2 ] | |||
Location |
Body (cg10156714) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.23E+00 | Statistic Test | p-value:1.95E-07; Z-score:-1.61E+00 | ||
Methylation in Case |
6.98E-01 (Median) | Methylation in Control | 8.60E-01 (Median) | ||
Studied Phenotype |
Breast cancer[ ICD-11:2C60-2C6Z] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon5 |
Methylation of SLC2A10 in breast cancer | [ 2 ] | |||
Location |
Body (cg07162198) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.86E+00 | Statistic Test | p-value:4.24E-02; Z-score:-8.70E-01 | ||
Methylation in Case |
7.21E-02 (Median) | Methylation in Control | 1.34E-01 (Median) | ||
Studied Phenotype |
Breast cancer[ ICD-11:2C60-2C6Z] | ||||
Experimental Material |
Patient tissue samples | ||||
Renal cell carcinoma |
5 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in clear cell renal cell carcinoma | [ 3 ] | |||
Location |
TSS1500 (cg23514532) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.48E+00 | Statistic Test | p-value:4.60E-05; Z-score:1.43E+00 | ||
Methylation in Case |
1.65E-01 (Median) | Methylation in Control | 1.12E-01 (Median) | ||
Studied Phenotype |
Renal cell carcinoma[ ICD-11:2C90] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon2 |
Methylation of SLC2A10 in clear cell renal cell carcinoma | [ 3 ] | |||
Location |
TSS200 (cg17298269) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.13E+00 | Statistic Test | p-value:2.85E-02; Z-score:3.87E-01 | ||
Methylation in Case |
9.83E-02 (Median) | Methylation in Control | 8.68E-02 (Median) | ||
Studied Phenotype |
Renal cell carcinoma[ ICD-11:2C90] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon3 |
Methylation of SLC2A10 in clear cell renal cell carcinoma | [ 3 ] | |||
Location |
Body (cg07162198) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.75E+00 | Statistic Test | p-value:7.72E-05; Z-score:2.89E+00 | ||
Methylation in Case |
1.96E-01 (Median) | Methylation in Control | 1.12E-01 (Median) | ||
Studied Phenotype |
Renal cell carcinoma[ ICD-11:2C90] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon4 |
Methylation of SLC2A10 in clear cell renal cell carcinoma | [ 3 ] | |||
Location |
Body (cg16117472) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.45E+00 | Statistic Test | p-value:2.58E-03; Z-score:1.64E+00 | ||
Methylation in Case |
4.85E-02 (Median) | Methylation in Control | 3.34E-02 (Median) | ||
Studied Phenotype |
Renal cell carcinoma[ ICD-11:2C90] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon5 |
Methylation of SLC2A10 in clear cell renal cell carcinoma | [ 3 ] | |||
Location |
Body (cg17550582) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.20E+00 | Statistic Test | p-value:5.18E-03; Z-score:6.88E-01 | ||
Methylation in Case |
2.99E-02 (Median) | Methylation in Control | 2.48E-02 (Median) | ||
Studied Phenotype |
Renal cell carcinoma[ ICD-11:2C90] | ||||
Experimental Material |
Patient tissue samples | ||||
Colon cancer |
5 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in colon adenocarcinoma | [ 4 ] | |||
Location |
TSS1500 (cg07176692) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.64E+00 | Statistic Test | p-value:2.00E-05; Z-score:-2.25E+00 | ||
Methylation in Case |
2.58E-01 (Median) | Methylation in Control | 4.24E-01 (Median) | ||
Studied Phenotype |
Colon cancer[ ICD-11:2B90] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon2 |
Methylation of SLC2A10 in colon adenocarcinoma | [ 4 ] | |||
Location |
TSS1500 (cg04934807) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:2.06E+00 | Statistic Test | p-value:4.23E-04; Z-score:7.24E+00 | ||
Methylation in Case |
2.60E-01 (Median) | Methylation in Control | 1.26E-01 (Median) | ||
Studied Phenotype |
Colon cancer[ ICD-11:2B90] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon3 |
Methylation of SLC2A10 in colon adenocarcinoma | [ 4 ] | |||
Location |
Body (cg19881928) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.45E+00 | Statistic Test | p-value:8.24E-04; Z-score:1.51E+00 | ||
Methylation in Case |
2.92E-01 (Median) | Methylation in Control | 2.01E-01 (Median) | ||
Studied Phenotype |
Colon cancer[ ICD-11:2B90] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon4 |
Methylation of SLC2A10 in colon adenocarcinoma | [ 4 ] | |||
Location |
Body (cg02262187) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.33E+00 | Statistic Test | p-value:4.22E-03; Z-score:-1.28E+00 | ||
Methylation in Case |
1.35E-01 (Median) | Methylation in Control | 1.80E-01 (Median) | ||
Studied Phenotype |
Colon cancer[ ICD-11:2B90] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon5 |
Methylation of SLC2A10 in colon adenocarcinoma | [ 4 ] | |||
Location |
3'UTR (cg22669120) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.33E+00 | Statistic Test | p-value:2.73E-05; Z-score:-1.50E+00 | ||
Methylation in Case |
3.90E-01 (Median) | Methylation in Control | 5.18E-01 (Median) | ||
Studied Phenotype |
Colon cancer[ ICD-11:2B90] | ||||
Experimental Material |
Patient tissue samples | ||||
Colorectal cancer |
8 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in colorectal cancer | [ 5 ] | |||
Location |
TSS1500 (cg23514532) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.01E+00 | Statistic Test | p-value:3.71E-02; Z-score:5.11E-02 | ||
Methylation in Case |
2.13E-01 (Median) | Methylation in Control | 2.10E-01 (Median) | ||
Studied Phenotype |
Colorectal cancer[ ICD-11:2B91] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon2 |
Methylation of SLC2A10 in colorectal cancer | [ 5 ] | |||
Location |
TSS200 (cg03940556) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.03E+00 | Statistic Test | p-value:6.61E-03; Z-score:-1.56E-01 | ||
Methylation in Case |
6.94E-02 (Median) | Methylation in Control | 7.15E-02 (Median) | ||
Studied Phenotype |
Colorectal cancer[ ICD-11:2B91] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon3 |
Methylation of SLC2A10 in colorectal cancer | [ 5 ] | |||
Location |
TSS200 (cg17298269) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.01E+00 | Statistic Test | p-value:8.91E-03; Z-score:7.80E-02 | ||
Methylation in Case |
2.41E-01 (Median) | Methylation in Control | 2.39E-01 (Median) | ||
Studied Phenotype |
Colorectal cancer[ ICD-11:2B91] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon4 |
Methylation of SLC2A10 in colorectal cancer | [ 5 ] | |||
Location |
Body (cg10156714) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.09E+00 | Statistic Test | p-value:5.32E-12; Z-score:-4.87E+00 | ||
Methylation in Case |
8.44E-01 (Median) | Methylation in Control | 9.21E-01 (Median) | ||
Studied Phenotype |
Colorectal cancer[ ICD-11:2B91] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon5 |
Methylation of SLC2A10 in colorectal cancer | [ 5 ] | |||
Location |
Body (cg07162198) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:3.42E+00 | Statistic Test | p-value:3.05E-09; Z-score:3.35E+00 | ||
Methylation in Case |
2.24E-01 (Median) | Methylation in Control | 6.54E-02 (Median) | ||
Studied Phenotype |
Colorectal cancer[ ICD-11:2B91] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon6 |
Methylation of SLC2A10 in colorectal cancer | [ 5 ] | |||
Location |
Body (cg17550582) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.28E+00 | Statistic Test | p-value:8.42E-06; Z-score:1.40E+00 | ||
Methylation in Case |
1.25E-01 (Median) | Methylation in Control | 9.79E-02 (Median) | ||
Studied Phenotype |
Colorectal cancer[ ICD-11:2B91] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon7 |
Methylation of SLC2A10 in colorectal cancer | [ 5 ] | |||
Location |
Body (cg16117472) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.06E+00 | Statistic Test | p-value:1.97E-04; Z-score:3.99E-01 | ||
Methylation in Case |
1.35E-01 (Median) | Methylation in Control | 1.27E-01 (Median) | ||
Studied Phenotype |
Colorectal cancer[ ICD-11:2B91] | ||||
Experimental Material |
Patient tissue samples | ||||
Hepatocellular carcinoma |
5 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in hepatocellular carcinoma | [ 6 ] | |||
Location |
TSS1500 (cg19631365) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.28E+00 | Statistic Test | p-value:2.60E-11; Z-score:-2.80E+00 | ||
Methylation in Case |
5.59E-01 (Median) | Methylation in Control | 7.15E-01 (Median) | ||
Studied Phenotype |
Hepatocellular carcinoma[ ICD-11:2C12.02] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon2 |
Methylation of SLC2A10 in hepatocellular carcinoma | [ 6 ] | |||
Location |
TSS1500 (cg27610561) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.01E+00 | Statistic Test | p-value:1.11E-04; Z-score:-4.82E-01 | ||
Methylation in Case |
8.33E-01 (Median) | Methylation in Control | 8.40E-01 (Median) | ||
Studied Phenotype |
Hepatocellular carcinoma[ ICD-11:2C12.02] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon3 |
Methylation of SLC2A10 in hepatocellular carcinoma | [ 6 ] | |||
Location |
TSS200 (cg08038974) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.13E+00 | Statistic Test | p-value:1.46E-02; Z-score:-3.06E-01 | ||
Methylation in Case |
9.14E-02 (Median) | Methylation in Control | 1.03E-01 (Median) | ||
Studied Phenotype |
Hepatocellular carcinoma[ ICD-11:2C12.02] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon4 |
Methylation of SLC2A10 in hepatocellular carcinoma | [ 6 ] | |||
Location |
TSS200 (cg03940556) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.08E+00 | Statistic Test | p-value:2.14E-02; Z-score:-2.59E-01 | ||
Methylation in Case |
9.12E-02 (Median) | Methylation in Control | 9.88E-02 (Median) | ||
Studied Phenotype |
Hepatocellular carcinoma[ ICD-11:2C12.02] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon5 |
Methylation of SLC2A10 in hepatocellular carcinoma | [ 6 ] | |||
Location |
Body (cg21207636) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.45E+00 | Statistic Test | p-value:1.68E-15; Z-score:-8.32E+00 | ||
Methylation in Case |
5.90E-01 (Median) | Methylation in Control | 8.52E-01 (Median) | ||
Studied Phenotype |
Hepatocellular carcinoma[ ICD-11:2C12.02] | ||||
Experimental Material |
Patient tissue samples | ||||
HIV infection |
6 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in HIV infection | [ 7 ] | |||
Location |
TSS1500 (cg23514532) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.42E+00 | Statistic Test | p-value:3.18E-05; Z-score:1.57E+00 | ||
Methylation in Case |
2.83E-01 (Median) | Methylation in Control | 1.99E-01 (Median) | ||
Studied Phenotype |
HIV infection[ ICD-11:1C62.Z] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon2 |
Methylation of SLC2A10 in HIV infection | [ 7 ] | |||
Location |
TSS200 (cg08038974) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.28E+00 | Statistic Test | p-value:2.97E-06; Z-score:1.45E+00 | ||
Methylation in Case |
2.76E-01 (Median) | Methylation in Control | 2.16E-01 (Median) | ||
Studied Phenotype |
HIV infection[ ICD-11:1C62.Z] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon3 |
Methylation of SLC2A10 in HIV infection | [ 7 ] | |||
Location |
TSS200 (cg03940556) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.25E+00 | Statistic Test | p-value:3.93E-05; Z-score:9.96E-01 | ||
Methylation in Case |
1.37E-01 (Median) | Methylation in Control | 1.10E-01 (Median) | ||
Studied Phenotype |
HIV infection[ ICD-11:1C62.Z] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon4 |
Methylation of SLC2A10 in HIV infection | [ 7 ] | |||
Location |
Body (cg07162198) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:2.00E+00 | Statistic Test | p-value:2.20E-05; Z-score:2.16E+00 | ||
Methylation in Case |
1.67E-01 (Median) | Methylation in Control | 8.37E-02 (Median) | ||
Studied Phenotype |
HIV infection[ ICD-11:1C62.Z] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon5 |
Methylation of SLC2A10 in HIV infection | [ 7 ] | |||
Location |
Body (cg10156714) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.03E+00 | Statistic Test | p-value:2.49E-03; Z-score:-1.16E+00 | ||
Methylation in Case |
8.59E-01 (Median) | Methylation in Control | 8.88E-01 (Median) | ||
Studied Phenotype |
HIV infection[ ICD-11:1C62.Z] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon6 |
Methylation of SLC2A10 in HIV infection | [ 7 ] | |||
Location |
Body (cg17550582) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.16E+00 | Statistic Test | p-value:2.95E-03; Z-score:7.30E-01 | ||
Methylation in Case |
7.90E-02 (Median) | Methylation in Control | 6.78E-02 (Median) | ||
Studied Phenotype |
HIV infection[ ICD-11:1C62.Z] | ||||
Experimental Material |
Patient tissue samples | ||||
Panic disorder |
2 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in panic disorder | [ 8 ] | |||
Location |
TSS1500 (cg27610561) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.07E+00 | Statistic Test | p-value:1.34E-02; Z-score:4.95E-01 | ||
Methylation in Case |
3.38E+00 (Median) | Methylation in Control | 3.17E+00 (Median) | ||
Studied Phenotype |
Panic disorder[ ICD-11:6B01] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon2 |
Methylation of SLC2A10 in panic disorder | [ 8 ] | |||
Location |
Body (cg07162198) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-9.02E-01 | Statistic Test | p-value:5.45E-03; Z-score:-4.84E-01 | ||
Methylation in Case |
-4.67E+00 (Median) | Methylation in Control | -4.22E+00 (Median) | ||
Studied Phenotype |
Panic disorder[ ICD-11:6B01] | ||||
Experimental Material |
Patient tissue samples | ||||
Papillary thyroid cancer |
3 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in papillary thyroid cancer | [ 9 ] | |||
Location |
TSS1500 (cg27610561) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.06E+00 | Statistic Test | p-value:1.36E-03; Z-score:-1.03E+00 | ||
Methylation in Case |
7.67E-01 (Median) | Methylation in Control | 8.12E-01 (Median) | ||
Studied Phenotype |
Papillary thyroid cancer[ ICD-11:2D10.1] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon2 |
Methylation of SLC2A10 in papillary thyroid cancer | [ 9 ] | |||
Location |
Body (cg16117472) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.07E+00 | Statistic Test | p-value:2.14E-03; Z-score:5.00E-01 | ||
Methylation in Case |
7.41E-02 (Median) | Methylation in Control | 6.92E-02 (Median) | ||
Studied Phenotype |
Papillary thyroid cancer[ ICD-11:2D10.1] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon3 |
Methylation of SLC2A10 in papillary thyroid cancer | [ 9 ] | |||
Location |
Body (cg07162198) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.15E+00 | Statistic Test | p-value:5.51E-03; Z-score:4.96E-01 | ||
Methylation in Case |
1.20E-01 (Median) | Methylation in Control | 1.05E-01 (Median) | ||
Studied Phenotype |
Papillary thyroid cancer[ ICD-11:2D10.1] | ||||
Experimental Material |
Patient tissue samples | ||||
Atypical teratoid rhabdoid tumor |
2 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in atypical teratoid rhabdoid tumor | [ 10 ] | |||
Location |
Body (cg07162198) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.14E+00 | Statistic Test | p-value:3.42E-03; Z-score:1.10E+00 | ||
Methylation in Case |
7.09E-01 (Median) | Methylation in Control | 6.22E-01 (Median) | ||
Studied Phenotype |
Atypical teratoid rhabdoid tumor[ ICD-11:2A00.1Y] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon2 |
Methylation of SLC2A10 in atypical teratoid rhabdoid tumor | [ 10 ] | |||
Location |
Body (cg10156714) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.09E+00 | Statistic Test | p-value:1.37E-02; Z-score:-4.83E-01 | ||
Methylation in Case |
6.44E-01 (Median) | Methylation in Control | 7.00E-01 (Median) | ||
Studied Phenotype |
Atypical teratoid rhabdoid tumor[ ICD-11:2A00.1Y] | ||||
Experimental Material |
Patient tissue samples | ||||
Lung adenocarcinoma |
2 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in lung adenocarcinoma | [ 11 ] | |||
Location |
Body (cg07162198) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.88E+00 | Statistic Test | p-value:9.10E-03; Z-score:3.43E+00 | ||
Methylation in Case |
2.01E-01 (Median) | Methylation in Control | 1.07E-01 (Median) | ||
Studied Phenotype |
Lung adenocarcinoma[ ICD-11:2C25.0] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon2 |
Methylation of SLC2A10 in lung adenocarcinoma | [ 11 ] | |||
Location |
Body (cg17550582) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.23E+00 | Statistic Test | p-value:3.13E-02; Z-score:1.69E+00 | ||
Methylation in Case |
1.18E-01 (Median) | Methylation in Control | 9.58E-02 (Median) | ||
Studied Phenotype |
Lung adenocarcinoma[ ICD-11:2C25.0] | ||||
Experimental Material |
Patient tissue samples | ||||
Pancretic ductal adenocarcinoma |
4 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in pancretic ductal adenocarcinoma | [ 12 ] | |||
Location |
Body (cg16909495) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.40E+00 | Statistic Test | p-value:5.94E-21; Z-score:3.06E+00 | ||
Methylation in Case |
5.05E-01 (Median) | Methylation in Control | 3.62E-01 (Median) | ||
Studied Phenotype |
Pancretic ductal adenocarcinoma[ ICD-11:2C10.0] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon2 |
Methylation of SLC2A10 in pancretic ductal adenocarcinoma | [ 12 ] | |||
Location |
Body (cg15828364) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.36E+00 | Statistic Test | p-value:3.03E-11; Z-score:1.63E+00 | ||
Methylation in Case |
3.62E-01 (Median) | Methylation in Control | 2.66E-01 (Median) | ||
Studied Phenotype |
Pancretic ductal adenocarcinoma[ ICD-11:2C10.0] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon3 |
Methylation of SLC2A10 in pancretic ductal adenocarcinoma | [ 12 ] | |||
Location |
Body (cg20209499) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.26E+00 | Statistic Test | p-value:9.98E-05; Z-score:1.20E+00 | ||
Methylation in Case |
6.72E-01 (Median) | Methylation in Control | 5.33E-01 (Median) | ||
Studied Phenotype |
Pancretic ductal adenocarcinoma[ ICD-11:2C10.0] | ||||
Experimental Material |
Patient tissue samples | ||||
Epigenetic Phenomenon4 |
Methylation of SLC2A10 in pancretic ductal adenocarcinoma | [ 12 ] | |||
Location |
Body (cg04066400) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.00E+00 | Statistic Test | p-value:1.97E-02; Z-score:-2.50E-02 | ||
Methylation in Case |
8.80E-01 (Median) | Methylation in Control | 8.80E-01 (Median) | ||
Studied Phenotype |
Pancretic ductal adenocarcinoma[ ICD-11:2C10.0] | ||||
Experimental Material |
Patient tissue samples | ||||
Prostate cancer |
2 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in prostate cancer | [ 13 ] | |||
Location |
Body (cg18869815) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:1.11E+00 | Statistic Test | p-value:3.37E-02; Z-score:1.48E+00 | ||
Methylation in Case |
8.38E-01 (Median) | Methylation in Control | 7.52E-01 (Median) | ||
Studied Phenotype |
Prostate cancer[ ICD-11:2C82] | ||||
Experimental Material |
Patient tissue samples | ||||
Systemic lupus erythematosus |
1 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Methylation of SLC2A10 in systemic lupus erythematosus | [ 14 ] | |||
Location |
Body (cg10156714) | ||||
Epigenetic Type |
Methylation | Experiment Method | Infinium HumanMethylation450 BeadChip | ||
Methylation Fold Change |
Fold Change:-1.01E+00 | Statistic Test | p-value:4.40E-03; Z-score:-3.20E-01 | ||
Methylation in Case |
8.76E-01 (Median) | Methylation in Control | 8.86E-01 (Median) | ||
Studied Phenotype |
Systemic lupus erythematosus[ ICD-11:4A40.0] | ||||
Experimental Material |
Patient tissue samples | ||||
Lymphoma |
1 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
Significant hypermethylation of SLC2A10 in lymphoma than that in healthy individual | ||||
Studied Phenotype |
Lymphoma [ICD-11:2B30] | ||||
The Methylation Level of Disease Section Compare with the Healthy Individual |
p-value:1.55E-26; Fold-change:0.532619712; Z-score:25.31383139 | ||||
DT methylation level in the diseased tissue of patients
DT methylation level in the normal tissue of healthy individuals
|
|||||
![]() |
![]() | ||||
microRNA |
|||||
Unclear Phenotype |
1 Epigenetic Phenomena Related to This Phenotype | Click to Show/Hide the Full List | |||
Epigenetic Phenomenon1 |
miR-335 directly targets SLC2A10 | [ 15 ] | |||
Epigenetic Type |
microRNA | Experiment Method | Microarray | ||
miRNA Stemloop ID |
miR-335 | miRNA Mature ID | miR-335-5p | ||
miRNA Sequence |
UCAAGAGCAAUAACGAAAAAUGU | ||||
miRNA Target Type |
Direct | ||||
Experimental Material |
Multiple cell lines of human | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.